Sou Hu Cai Jing·2026-01-13 03:23Core Viewpoint - Nvidia and Eli Lilly announced a joint investment of $1 billion to establish an AI drug research laboratory in San Francisco, aimed at accelerating drug development processes [1][5]. Group 1: Investment Details - The $1 billion investment will be allocated over five years for laboratory infrastructure, computing power, and talent deployment [5]. - The collaboration will involve Nvidia engineers working alongside Eli Lilly's experts in biology, science, and medicine to advance medical research, with operations set to begin in early 2023 [5]. Group 2: Strategic Implications - Eli Lilly's CEO, David Ricks, emphasized that combining vast data and scientific knowledge with Nvidia's computational capabilities could fundamentally transform drug development methods [5]. - Nvidia has previously invested in biotechnology company Recursion and established partnerships with leading firms in the healthcare sector, indicating a strategic focus on the AI ecosystem [5]. - Nvidia's CEO, Jensen Huang, stated that AI is transforming every industry, with its most profound impact expected in the life sciences sector [7].